A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Obesity is associated with an increased cardiovascular risk. Drugs with glucagon-like peptide-1 receptor agonist (arGLP-1) action for overweight/obesity, such as liraglutide, semaglutide, and tirzepatide, have shown improvements in weight and body co…
"Ozempic face" and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic infl…
INTRODUCTION: Although the association between semaglutide use for diabetes or obesity and non-arteritic ischemic optic neuropathy (NAION) has been investigated, the relative risk has not been established in large, racially diverse populations. Given…
BACKGROUND: We retrospectively evaluated the efficacy of using additional obesity management medications (OMMs) within the first year after undergoing laparoscopic sleeve gastrectomy (LSG). METHODS: We retrospectively analyzed 246 patients who underw…
PURPOSE: Sleeve gastrectomy (LSG) is effective, but weight regain (WR) and variable hormonal responses challenge long-term outcomes. This study evaluated long-term weight and incretin trajectories after LSG in adolescents and assessed the impact of a…
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering…
BACKGROUND: This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and…
<p>Introduction: Pathogenic heterozygous melanocortin-4 receptor (MC4R) variants are the most common cause of monogenic obesity, affecting central satiety and appetite regulatory areas of the brain. Case Presentations: We report a pedigree with a pat…
BACKGROUND: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide…
The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigationa…
IMPORTANCE: Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these find…
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithro…
INTRODUCTION: Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and patient-reported outcomes of oral sem…
AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages. METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of C…
Cardiovascular-Kidney-Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the…
BACKGROUND: The purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semagl…
Ozempic and related semaglutide drugs represent a popular new strategy to address obesity in the United States, yet uptake of these medications has sparked opposition highlighting concerns about off-label drug use policies, drug safety, supply shorta…